Sort   by:  
 Page size 
TranscriptomicsEverolimus protects podocytes via stabilizing TUBB2B and DCDC2 expression
Glomerular podocytes are highly differentiated cells that are key components of the kidney filtration units. The podocyte cytoskeleton builds the basis for the dynamic podocyte cytoarchitecture and plays a central role for proper podocyte function. Recent studies implicate that immunosuppressive age...
ORGANISM(S): Homo sapiens 
2015-09-09 | E-GEOD-66107 | biostudies-arrayexpress
ProteomicsChemical proteomics reveals that the anticancer drug everolimus affects ubiquitin-proteasome system
Rapamycin is a natural antifungal, immunosuppressive, and antiproliferative compound allosterically inhibiting mTOR complex 1. The ubiquitin-proteasome system (UPS) responsible for protein turnover is usually not listed among the pathways affected by mTOR signaling; however, a number of reports indi...
ORGANISM(S): Homo sapiens (Human) 
2024-02-09 | PXD045774 | Pride
Ubiquitin-proteasome system Expression proteomics Everolimus Ubiquitination Rapamycin Diglycine modification Semi-tryptic peptides Drug treatment Cell line 
TranscriptomicsEverolimus
The effect of Everolimus (RAD001) on primary isolated human dermal microvascular endothelial (HDMVEC) and Fibroblast Cells as well as human glioblastoma brain tumor cell line (U87).
ORGANISM(S): Homo sapiens 
2013-11-12 | E-MEXP-3802 | biostudies-arrayexpress
GenomicsEverolimus and sunitinib induce infantile hemangiomas cell apoptosis through P53 activation
Everolimus and sunitinib induce infantile hemangiomas cell apoptosis through P53 activation
PRJNA1173570 | ENA
GenomicsGene expression changes in 786-O cells in response to Everolimus, SGI-1027, or their combination.
Gene expression changes in 786-O cells in response to Everolimus, SGI-1027, or their combination.
PRJNA1011338 | ENA
GenomicsGene expression profiling of pre-operative mTOR inhibitor everolimus treatment in breast cancer
Gene expression profiling of pre-operative mTOR inhibitor everolimus treatment in breast cancer
PRJNA488625 | ENA
GenomicsThe development of mucositis by everolimus treatment of an oral 3D tissue model
The development of mucositis by everolimus treatment of an oral 3D tissue model
PRJNA882024 | ENA
GenomicsNCTN: EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study (S0931)
NCTN: EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study (S0931)
PRJNA1307686 | ENA
GenomicsNCTN: EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study (S0931)
NCTN: EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study (S0931)
PRJNA1307687 | ENA
TranscriptomicsEverolimus protects podocytes via stabilizing TUBB2B and DCDC2 expression
Glomerular podocytes are highly differentiated cells that are key components of the kidney filtration units. The podocyte cytoskeleton builds the basis for the dynamic podocyte cytoarchitecture and plays a central role for proper podocyte function. Recent studies implicate that immunosuppressive age...
ORGANISM(S): Homo sapiens 
2015-09-09 | GSE66107 | GEO
Sort   by:  
 Page size